AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Moderna, Inc. Director's Dealing 2023

May 5, 2023

30610_dirs_2023-05-05_003e06b1-40a5-48a3-89ac-7e84d2a79996.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Moderna, Inc. (MRNA)
CIK: 0001682852
Period of Report: 2023-05-03

Reporting Person: AFEYAN NOUBAR (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-05-03	Stock Option (Right to Buy)	$130.14	A	6134	Acquired	2033-05-03	Common Stock (6134)	Direct

Footnotes

F1: This option will become fully vested and exercisable on the earlier of May 3, 2024, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service.